...
首页> 外文期刊>Journal of Neuroimmunology: Official Bulletin of the Research Committee on Neuroimmunology of the World Federation of Neurology >Intracerebroventricular injection of an agonist-like monoclonal antibody to adenosine A(2A) receptor has antinociceptive effects in mice.
【24h】

Intracerebroventricular injection of an agonist-like monoclonal antibody to adenosine A(2A) receptor has antinociceptive effects in mice.

机译:脑室内注射腺苷A(2A)受体激动剂样单克隆抗体在小鼠中具有镇痛作用。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Adenosine is a modulator of nociceptive pathways, both at the spinal and supraspinal levels. Adenosine A(1) and A(2A) receptors (A(1)R, A(2A)R) are expressed in the basal ganglia where they are the target of caffeine, the most widely use psychoactive drug which acts as an antagonist to both types of receptors. Given the controversial role of A(2A)R versus A(1)R in modulating pain in brain areas, mice received intracerebroventricular injection of Adonis, an agonist-like monoclonal antibody with high specificity for the A(2A)R and were subjected to behavioral tests investigating nociceptive thresholds. We report that Adonis led to a significant dose-dependent increase in hot-plate and tail-flick latencies in mice and that such increase was prevented by caffeine and ZM 241385, a specific A(2A)R antagonist. The Adonis antinociceptive effects were also inhibited by naloxone, a non selective antagonist for opioid receptors, suggesting that Adonis acts, at least in part, through the stimulation of the endogenous opioid system. These results confirm the A(2A)R as a target for pain control and Adonis as a potential drug with therapeutic interest.
机译:腺苷在脊髓和脊髓上水平均是伤害感受途径的调节剂。腺苷A(1)和A(2A)受体(A(1)R,A(2A)R)在基底神经节中表达,它们是咖啡因的靶标,咖啡因是最广泛使用的精神活性药物,可作为咖啡因的拮抗剂两种类型的受体。鉴于A(2A)R与A(1)R在调节大脑区域疼痛中的争议作用,小鼠接受了脑室内注射Adonis(一种对A(2A)R具有高特异性的激动剂样单克隆抗体),并接受了调查伤害性阈值的行为测试。我们报告说,Adonis导致小鼠热板和甩尾潜伏期的剂量依赖性显着增加,而咖啡因和ZM 241385(一种特定的A(2A)R拮抗剂)阻止了这种增加。阿多尼斯的抗伤害感受作用也被纳洛酮抑制,纳洛酮是阿片受体的非选择性拮抗剂,表明阿多尼斯至少部分地通过刺激内源性阿片样物质系统起作用。这些结果证实了A(2A)R是控制疼痛的靶点,而Adonis是具有治疗意义的潜在药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号